RECURSION PHARMACEUTICALS-A (RXRX) Stock Price, Quote, News and Overview
NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD
RXRX Quote, Performance and Key Statistics
RECURSION PHARMACEUTICALS-A
NASDAQ:RXRX (2/12/2025, 8:00:01 PM)
Premarket: 8.3 -0.04 (-0.48%)8.34
+0.68 (+8.88%)
The current stock price of RXRX is 8.34 USD. In the past month the price increased by 31.96%. In the past year, price decreased by -36.58%.
RXRX Latest News and Analysis
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to...
3 Monster Stocks to Hold for the Next 10 Years
A handful of companies are in the right place at the right time with the right product or service.
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
RXRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 341.06B | ||
| AMGN | AMGEN INC | 14.89 | 158.60B | ||
| GILD | GILEAD SCIENCES INC | 22.41 | 128.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1562.76 | 116.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 72.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.82B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.80B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.1 | 19.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 16.55B |
Related stock screener links
About RXRX
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 500 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Company Info
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101 US
CEO: Christopher Gibson
Employees: 500
Company Website: https://www.recursion.com/
Investor Relations: https://ir.recursion.com/
Phone: 13852690203
RXRX FAQ
What is the stock price of RXRX?
The current stock price of RXRX is 8.34 USD.
What is the symbol for RECURSION PHARMACEUTICALS-A stock?
The exchange symbol of RECURSION PHARMACEUTICALS-A is RXRX and it is listed on the Nasdaq exchange.
On which exchange is RXRX stock listed?
RXRX stock is listed on the Nasdaq exchange.
Is RXRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RXRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RXRX.
Does RXRX stock pay dividends?
RXRX does not pay a dividend.
When does RXRX stock report earnings?
RXRX will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of RXRX?
RXRX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.55).
What is the Short Interest ratio of RXRX stock?
The outstanding short interest for RXRX is 18.33% of its float.
RXRX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RXRX. When comparing the yearly performance of all stocks, RXRX is a bad performer in the overall market: 62.83% of all stocks are doing better.
RXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RXRX. While RXRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
RXRX Financial Highlights
Over the last trailing twelve months RXRX reported a non-GAAP Earnings per Share(EPS) of -1.55. The EPS increased by -6.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52% | ||
| ROE | -72.01% | ||
| Debt/Equity | 0.04 |
RXRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to RXRX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -2.93% and a revenue growth 35.69% for RXRX